User profiles for Clio P. Mavragani

Clio P. Mavragani

Department of Physiology, National and Kapodistrian University of Athens
Verified email at med.uoa.gr
Cited by 6921

The geoepidemiology of Sjögren's syndrome

CP Mavragani, HM Moutsopoulos - Autoimmunity reviews, 2010 - Elsevier
Sjogren's syndrome (SS) is a slowly progressing autoimmune disease, affecting predominantly
middle-aged women, with a female to male ratio reaching 9:1. It is characterized by …

Sjögren's syndrome

CP Mavragani, GE Fragoulis… - The Autoimmune …, 2014 - Elsevier
Sjögren’s syndrome (SjS) is a systemic autoimmune disease, characterized by the presence
of periductal lymphocytic infiltrations in salivary and lachrymal glands resulting in oral and …

[HTML][HTML] Sjögren syndrome

CP Mavragani, HM Moutsopoulos - Cmaj, 2014 - Can Med Assoc
• Mild chronic renal compromise34 continued association with antibodies against neuropeptides.
42 Increased rates of neuroticism, psychoticism, obsessiveness, hypochondriasis, …

A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies

…, H Alexanderson, CP Mavragani… - Annals of the …, 2008 - ard.bmj.com
Objective: To investigate the effect of the tumour necrosis factor (TNF) blocking agent
infliximab in patients with treatment-resistant inflammatory myopathies. Methods: A total of 13 …

Type I and II interferon signatures in Sjogren's syndrome pathogenesis: contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis

…, M Koutsilieris, MK Crow, CP Mavragani - Journal of …, 2015 - Elsevier
Both type I and II interferons (IFNs) have been implicated in the pathogenesis of Sjogren's
syndrome (SS). We aimed to explore the contribution of type I and II IFN signatures in the …

[HTML][HTML] Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use

S Fragkioudaki, CP Mavragani, HM Moutsopoulos - Medicine, 2016 - journals.lww.com
The heightened risk of non-Hodgkin lymphoma (NHL) development in primary Sjogren
syndrome (SS) is well established. Several adverse clinical and laboratory predictors have been …

Augmented interferon‐α pathway activation in patients with Sjögren's syndrome treated with etanercept

CP Mavragani, TB Niewold… - … : Official Journal of …, 2007 - Wiley Online Library
Objective. Recent clinical trials suggest that etan-ercept is ineffective in controlling Sjögren’s
syndrome (SS). To address the hypothesis that tumor necrosis factor blockade can result in …

Cardiovascular disease in systemic lupus erythematosus: a comprehensive update

M Giannelou, CP Mavragani - Journal of autoimmunity, 2017 - Elsevier
Heightened rates of both cardiovascular (CV) events and subclinical atherosclerosis,
documented by imaging and vascular function techniques are well established in systemic lupus …

Expression of long interspersed nuclear element 1 retroelements and induction of type I interferon in patients with systemic autoimmune disease

CP Mavragani, I Sagalovskiy, Q Guo… - Arthritis & …, 2016 - Wiley Online Library
Objective Increased expression of type I interferon (IFN) and a broad signature of type I IFN–induced
gene transcripts are observed in patients with systemic lupus erythematosus (SLE) …

Activation of the type I interferon pathway in primary Sjogren's syndrome

CP Mavragani, MK Crow - Journal of autoimmunity, 2010 - Elsevier
Sjogren’s syndrome (SS), a chronic autoimmune systemic disease affecting middle aged
women, is characterized by lymphocytic infiltration of the salivary and lachrymal glands …